This HTML5 document contains 49 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n7http://linked.opendata.cz/resource/domain/vavai/subjekt/
n6http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n13http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n18http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064165%3A_____%2F13%3A00011739%21RIV14-MZ0-00064165/
n4http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064165%3A_____%2F13%3A00011739%21RIV14-MZ0-00064165
rdf:type
n6:Vysledek skos:Concept
rdfs:seeAlso
http://dx.doi.org/10.1007/s13317-012-0045-0
dcterms:description
Purpose: to (1) examine the occurrence and concentrations of aPS/PT and aPL in inflammatory bowel disease (IBD) patients at the beginning of and during anti-TNFalpha therapy with infliximab; (2) investigate the link of the aPS/PT and aPL presence with antibodies to infliximab (ATI) formation; and (3) examine possible clinical consequences of aPS/PT and/or aPL positivity in IBD patients. Purpose: to (1) examine the occurrence and concentrations of aPS/PT and aPL in inflammatory bowel disease (IBD) patients at the beginning of and during anti-TNFalpha therapy with infliximab; (2) investigate the link of the aPS/PT and aPL presence with antibodies to infliximab (ATI) formation; and (3) examine possible clinical consequences of aPS/PT and/or aPL positivity in IBD patients.
dcterms:title
Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases
skos:prefLabel
Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases
skos:notation
RIV/00064165:_____/13:00011739!RIV14-MZ0-00064165
n6:predkladatel
n7:ico%3A00064165
n3:aktivita
n17:I n17:S
n3:aktivity
I, S
n3:cisloPeriodika
1
n3:dodaniDat
n4:2014
n3:domaciTvurceVysledku
n12:9963065 n12:9451935 n12:8705097
n3:druhVysledku
n16:J
n3:duvernostUdaju
n11:S
n3:entitaPredkladatele
n18:predkladatel
n3:idSjednocenehoVysledku
96069
n3:idVysledku
RIV/00064165:_____/13:00011739
n3:jazykVysledku
n19:eng
n3:klicovaSlova
Antibodies to infliximab; Antiphospholipid antibodies; Phosphatidylserine-dependent antiprothrombin antibodies; Ulcerative colitis; Crohn's disease; Inflammatory bowel diseases
n3:klicoveSlovo
n5:Ulcerative%20colitis n5:Inflammatory%20bowel%20diseases n5:Crohn%27s%20disease n5:Antibodies%20to%20infliximab n5:Antiphospholipid%20antibodies n5:Phosphatidylserine-dependent%20antiprothrombin%20antibodies
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[562026269F4E]
n3:nazevZdroje
Autoimmunity Highlights
n3:obor
n15:EC
n3:pocetDomacichTvurcuVysledku
3
n3:pocetTvurcuVysledku
6
n3:rokUplatneniVysledku
n4:2013
n3:svazekPeriodika
4
n3:tvurceVysledku
Zima, Tomáš Ďuricová, Dana Bortlík, Martin Lukáš, Milan Janatková, Ivana Malíčková, Karin
s:issn
2038-0305
s:numberOfPages
6
n13:doi
10.1007/s13317-012-0045-0